Unbound MEDLINE

Pharmacokinetics of transdermal buprenorphine patch in the elderly.

Abstract

PURPOSE
Transdermal buprenorphine patches provide comparable pain relief to that of low-potency opioids in elderly individuals. However, specific data on their use in elderly individuals is limited. This study investigated and compared the PK of buprenorphine transdermal patches in elderly (≥ 75 years) versus younger (50-60 years) individuals.
METHODS
This was a multiple-dose, open-label, parallel-group study in healthy volunteers split into two age groups (younger, 50-60 years; elderly, ≥ 75 years) with 37 individuals in each. Study participants received two consecutive 7-day buprenorphine 5 μg/h transdermal patch applications, and blood samples were collected on the week of the second patch application [day 7 (predose), days 8, 9, 10, 12, and 14] to determine PK at steady state. Pharmacokinetic parameters were determined for buprenorphine and norbuprenorphine. Safety was assessed by analyzing adverse events, hematology, clinical chemistry, urine analysis, vital signs, electrocardiogram (ECG), and physical examinations.
RESULTS
The area under the plasma concentration-time curve at steady state (AUC(tau)), measured over one dosing interval, was similar for elderly [mean ± standard deviation (SD) 9,940 pg/h/ml (4,827 pg/h/ml] and younger [mean ± SD 11,309 (3,670 pg/h/ml] individuals. Bioequivalence was not demonstrated between groups, which may be attributable to the relatively high level of variability in individual plasma profiles. More adverse events were reported by younger (216) than elderly (164) study participants.
CONCLUSIONS
No dosage alterations are necessary for PK reasons when treating elderly people with buprenorphine transdermal patches.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors

    Al-Tawil N, Odar-Cederlöf I, Berggren AC, Johnson HE, Persson J

    Institution

    Karolinska Trial Alliance Phase 1 Unit, M62, Karolinska University Hospital, Stockholm, Sweden.

    Source

    European journal of clinical pharmacology 69:2 2013 Feb pg 143-9

    MeSH

    Administration, Cutaneous
    Aged
    Aged, 80 and over
    Aging
    Analgesics, Opioid
    Area Under Curve
    Buprenorphine
    Female
    Humans
    Male
    Middle Aged
    Transdermal Patch

    Pub Type(s)

    Clinical Trial, Phase I
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22706617